This week’s Weekly Dose covers new Endocrine Society guidelines on preexisting diabetes in pregnancy and primary aldosteronism screening, a digital asthma management tool that improved symptoms but revealed disparities, public perceptions of physicians using AI, evidence linking GLP-1 receptor agonists to reduced dementia risk, and the FDA’s first approved treatment for chronic hand eczema.

In this episode of the Weekly Dose, Patient Care editors review recent studies on key health care topics. Highlights include health care professionals’ views on diets and nutrition training, the link between cycling and reduced dementia risk, the role of tau pathology in late-life depression, the safety of aluminum in childhood vaccines, and the impact of maternal depression on parenting.

In this episode of Weekly Dose, we explore a range of clinical studies, from patient preferences in atopic dermatitis treatment to the impact of social determinants of health on hormonal therapy use in midlife women. We also discuss the FDA's Breakthrough Device designation for a multi-cancer detection test, the challenges in deimplementing low-value cancer screenings, and the impact of obesity pharmacotherapy adherence on weight loss outcomes. Tune in for these important insights shaping clinical practice across multiple specialties.

In this episode of Weekly Dose, we cover a wide range of important clinical findings. We discuss the feasibility of digital cognitive assessments for Alzheimer disease screening in primary care, patient preferences for atopic dermatitis treatments, and the impact of social determinants of health on hormonal therapy use among midlife women. Additionally, we explore the FDA's Breakthrough Device designation for a multi-cancer detection test and new findings linking the quality of low-carb and low-fat diets to coronary heart disease prevention. Tune in for these key insights that are shaping clinical practice.

 In this episode of Weekly Dose, we cover the latest clinical research, including a study linking cannabis-related ED visits to a higher risk of dementia, and new findings on hormonal contraceptives and postpartum depression. We also explore the FDA’s approval of the first blood test for Alzheimer disease diagnosis, gepotidacin as an oral treatment for gonorrhea, and the growing global burden of atopic dermatitis in older adults. Tune in for a comprehensive overview of these important studies and their clinical implications. 

In this episode of Weekly Dose, we round up the latest clinical research, featuring key studies on patient navigation for follow-up colonoscopy, the FDA-approved Teal Wand for at-home cervical cancer screening, and the effectiveness of telemedicine in managing acute respiratory tract infections. We also explore the real-world data on upadacitinib for Crohn disease and the impact of AI in improving mammography accuracy. Tune in for a comprehensive look at these groundbreaking studies and their implications for clinical practice. 

In this episode of The Weekly Dose, Patient Care editors speaks with Elizabeth Mollard, PhD, about new research she presented at the 2025 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting that highlighted how Medicaid policy directly impacts postpartum depression (PPD) diagnosis rates. Drawing on national data, Mollard explains that more generous Medicaid coverage—especially extended postpartum eligibility—leads to more frequent diagnoses of PPD, a finding that underscores the critical importance of access to care. The conversation covers clinical implications, the effects of the COVID-19-era Medicaid expansion and wind-down, and practical recommendations for clinicians and policymakers to improve mental health outcomes for postpartum patients.

This is not indicative of higher prevalence, but rather of improved access and identification of women in need of care.

When postpartum Medicaid coverage was expanded nationally, diagnosis rates rose. After the expansion ended, diagnoses dropped—likely due to decreased access, not decreased incidence.

Mollard recommends screening beyond the six-week postpartum visit and ensuring continuity of care for those who screen positive.

Coverage should include not only screening, but also counseling, medications like zuranolone, and extended eligibility through 12 months postpartum.

Many working women earn too much to qualify for Medicaid but too little to afford private insurance, making extended postpartum coverage essential to reduce disparities and prevent worsening mental health outcomes.